CorMedix Inc. Form 8-K March 09, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2015

CORMEDIX INC. (Exact Name of Registrant as Specified in Charter)

Delaware	001-34673	20-5894890
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File	Identification No.)
	Number)	

1430 U.S. Highway 206, Suite 200, 07921 Bedminster, NJ (Address of Principal Executive (Zip Code) Offices)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

745 Route 202-206, Suite 303, Bridgewater, NJ 08807 (Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-comme	encement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-comm	encement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.03 Material Modification to Rights of Security Holders.

On March 9, 2015, we issued a press release to clarify that the extension to April 30, 2015 of the expiration date for our publicly traded warrants is applicable to all of the publicly traded warrants. The expiration date for all publicly traded warrants is now April 30, 2015.

A copy of the press release announcing the extension is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release dated March 9, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: March 9, 2015

By:

/s/ Randy Milby Randy Milby Chief Executive Officer